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Background: Zika virus (ZIKV) emerged in May 2015 in Brazil, from which it spread
to many other countries in Latin America. Cases of ZIKV infection were eventually also
reported in Curaçao (January 2016) and Bonaire (February 2016).
Methods: In the period of 16 December 2015 until 26 April 2017, serum, EDTA-plasma
or urine samples were taken at Medical Laboratory Services (MLS) from patients
on Curaçao and tested in qRT-PCR at the Erasmus Medical Centre (EMC) in the
Netherlands. Between 17 October 2016 until 26 April 2017 all samples of suspected
ZIKV-patients collected on Curaçao, as well as on Bonaire, were tested at MLS. Paired
urine and/or serum samples from patients were analyzed for ZIKV shedding kinetics,
and compared in terms of sensitivity for ZIKV RNA detection. Furthermore, the age and
gender of patients were used to determine ZIKV incidence rates, and their geozone
location to determine the spatial distribution of ZIKV cases.
Results: In total, 781 patients of 2820 tested individuals were found qRT-PCR-positive
for ZIKV on Curaçao. The first two ZIKV cases were diagnosed in December 2015. A
total of 112 patients of 382 individuals tested qRT-PCR-positive for ZIKV on Bonaire.
For both islands, the peak number of absolute cases occurred in November 2016, with
247 qRT-PCR confirmed cases on Curaçao and 66 qRT-PCR-positive cases on Bonaire.
Overall, a higher proportion of women than men was diagnosed with ZIKV on both
islands, as well as mostly individuals in the age category of 25–54 years old. Furthermore,
ZIKV cases were mostly clustered in the east of the island, in Willemstad.
Conclusions: ZIKV cases confirmed by qRT-PCR indicate that the virus was circulating
on Curaçao between at least December 2015 and March 2017, and on Bonaire between
at least October 2016 and February 2017, with peak cases occurring in November
2016. The lack of preparedness of Curaçao for the ZIKV outbreak was compensated
by shipping all samples to the EMC for diagnostic testing; however, both islands will
need to put the right infrastructure in place to enable a rapid response to an outbreak of
any new emergent virus in the future.
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INTRODUCTION
Zika virus (ZIKV) is an arbovirus that belongs to the Flaviviridae
family, genus Flavivirus, and is transmitted through the bite
of infected Aedes aegypti mosquitoes, via sexual contact (1–
3), or from mother to fetus (4). ZIKV infection is often
asymptomatic or otherwise presents with mild symptoms such
as fever, macopapular rash, conjunctivitis, myalgia, and headache
(5). In a small number of cases, ZIKV infection can result in
serious complications such as Guillain-Barré syndrome (6–10),
maculopathy (11–13), or microcephaly in newborns when the
mother is infected with the virus during pregnancy (14–18).
Historically, since its discovery in Uganda in 1947, ZIKV
was confined to Africa resulting only in sporadic cases of mild
disease. In 2007, however, this pattern changed when the first
major outbreak of ZIKV occurred in Yap (Federal States of
Micronesia) where ∼73% of the population was infected and
symptomatic disease developed in ∼18% of infected persons
(19). Since then, ZIKV spread rapidly across the Pacific Ocean,
causing outbreaks in French Polynesia (20), Cook Islands
(20), Easter Island (21), New Caledonia (22), until eventually
emerging in the Americas (23). Here it was first reported
in Brazil in continental South America in May 2015, after
which the virus spread to other Latin American countries, such
as Colombia (October 2015), Surinam, El Salvador, Mexico,
Guatemala, Paraguay, Venezuela (November 2015), Panama,
Honduras, French Guiana, Martinique, Puerto Rico (December
2015), Maldives, Guyana, Ecuador, Barbados, Bolivia, Haiti,
Saint Martin, Dominican Republic, Nicaragua, Jamaica, Curaçao,
Costa Rica (January 2016), Bonaire and Aruba (February
2016) (24, 25). In Brazil alone, it has been estimated that
between 440,000 and 1.3 million persons were infected with
ZIKV in 2015 (26), and around 2366 cases of ZIKV-associated
microcephaly/CNS malformations have been reported (as of
February 2017, www.statista.com). Since then, the epidemic
continued to spread, and the total number of infected persons
and children with congenital ZIKV syndrome still remains to
be determined.
Curaçao, a nation of almost 150,000 inhabitants, is known
for its circulation of A. aegypti transmitted viruses, such as
dengue virus (DENV) and chikungunya virus (CHIKV). DENV
has been endemic on Curaçao for decades and outbreaks of the
virus occur here every few years. The most recent outbreak of
dengue occurred in 2014, where Curaçao health authorities had
reported 194 suspected and 20 confirmed cases of dengue at
the end of August (27). In June of the same year, the first case
of CHIKV was also reported, which was the start of a major
outbreak on the island that lasted until February 2015. By the
end of November 2014, 1,838 suspected and 835 confirmed cases
Abbreviations: ZIKV, Zika virus; DENV, dengue virus; CHIKV, chikungunya
virus; IgM, immunoglobulin M; IgG, immunoglobulin G; ELISA, enzyme-
linked immunosorbent assay; qRT-PCR, quantitative real-time polymerase chain
reaction; RNA, ribonucleic acid; EDTA, ethylenediaminetetraacetic acid; WHO,
World Health Organization; NAT, nucleic acid testing; MLS, Medical Laboratory
Services; EMC, Erasmus Medical Center; NS2A, non-structural protein 2A; PDV,
phocine distemper virus; CT, cycle threshold; FTD, Fast Track Diagnostics; ADC,
Analytisch Diagnostisch Centrum; HIV, human immunodeficiency virus.
of CHIKV had been reported (28). Dengue is also endemic on
Bonaire, a nation with almost 19,000 inhabitants, but not many
reports are available.
Due to the high degree of serological cross-reactivity between
flaviviruses, confirmation of infection poses a challenge. As IgM
is thought to be more specific than IgG, detection of IgM against
ZIKV by ELISA represents a possibility; however, cross-reactivity
of DENV and ZIKV IgMhas been demonstrated (29). Thismeans
that confirmative neutralization assays would still be required.
As a result, confirmation of flavivirus infections is mostly based
on detection of viral RNA in serum by using quantitative real-
time PCR (qRT-PCR). However, for several arboviruses such
as DENV or ZIKV, the level of viremia present in the blood
during the symptomatic phase is often very low, which makes
detection problematic. The use of urine as an alternative matrix
for detecting ZIKV RNA was investigated by several laboratories
and was found to be a good alternative to serum, EDTA-plasma
and saliva, due to the higher levels of RNA found, and the longer
period of time that urine was found positive after the onset of
symptoms (>10–20 days) (30, 31). In contrast, another study
demonstrated detection of ZIKV in whole blood for a longer
period of time compared to urine and serum (32). Based on
these observations, official World Health Organization (WHO)
interim recommendations included using either whole blood,
serum, or urine for nucleic acid testing (NAT), and serum for IgM
detection (33). The routine confirmation of serological results
by virus neutralization assays was not recommended as it was
considered unfeasible.
To define the scope of the ZIKV outbreak on Curaçao and
Bonaire, we determined the number of confirmed ZIKV cases
based on qRT-PCR diagnostics, the incidence rates of infection
in patients in terms of age and gender, as well as the geospatial
distribution of ZIKV cases on Curaçao. In addition, paired
urine samples from Curaçao were assessed for ZIKV shedding
kinetics, while paired urine and serum samples from Bonaire
were compared for sensitivity of ZIKV RNA detection.
METHODS
In the period of 16 December 2015 until 26 April 2017,
serum, EDTA-plasma or urine samples were taken at Medical
Laboratory Services (MLS) from patients on Curaçao presenting
with symptoms resembling ZIKV infection, such as fever, rash,
headache or conjunctivitis. Between 16 December 2015 and
15 October 2016, the collected samples were inactivated and
stabilized in MagnaPure lysis buffer (Roche Diagnostics, Almere,
the Netherlands) and shipped to the diagnostic laboratory
of the Erasmus Medical Centre (EMC) in Rotterdam, the
Netherlands, where ZIKV RNA was tested by an ISO15189:2012
validated, internally controlled lab-developed real-time semi-
quantitative qRT-PCR. In short, total nucleic acids were isolated
using an external lysis protocol on the MagNA Pure LC
robotics system (Roche Diagnostics) and subsequently tested
in two independent qRT-PCRs using TaqMan R© 1-Step Fast-
Virus Master Mix (Thermo Fisher Scientific, Bleiswijk, the
Netherlands) and primers targeting the envelope and the NS2A,
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TABLE 1 | Lab-developed qRT-PCR primers and probe used for diagnostics of ZIKV.
Name Sequence (5′-3′) Conc.
(nM)
Target PCR product
(bp)
References
ZIKV_1086 CCGCTGCCCAACACAAG 600 Envelope 77 (29)
ZIKV_1107 FAM-AGCCTACCTTGACAAGCAGTCAGACACTCAA-BHQ1 100
ZIKV_1162c CCACTAACGTTCTTTTGCAGACAT 600
Zika2_fwd CTTGGAGTGCTTGTGATT 600 NS2A 187 (34)
Zika2_ probe FAM-AGAAGAGAATGACCACAAAGATCA-BHQ1 100
Zika2_rev CTCCTCCAGTGTTCATTT 600
PDV fwd CGGGTGCCTTTTACAAGAAC 600 Heamagglutinine 78 (35)
PDV probe Cy5-ATGCAAGGGCCAATT-MGB 200
PDV rev TTCTTTCCTCAACCTCGTCC 150
PDV, phocine distemper virus (internal control); BHQ, black hole quencher.
TABLE 2 | Number of samples collected and tested, and the number of patients
tested in qRT-PCR during the ZIKV outbreak on Curaçao and Bonaire.
Curaçao Bonaire
No. of samples collected 3,833 744
No. of patients 2,820 382
No. of samples tested in qRT-PCR 2,044 599
No. of patients tested in qRT-PCR 1,685 358
No. of qRT-PCR positive samples 815 129
No. of qRT-PCR positive patients 781 112
No. of patients submitting paired samples
for qRT-PCR
324 –
No. of patients testing qRT-PCR positive for
first sample
70 –
No. of patients testing qRT-PCR positive for
second sample
32 –
No. of patients submitting paired urine and
serum samples
– 262
No. of patients submitting paired urine and
serum samples for qRT-PCR
– 183
No. of patients testing qRT-PCR positive for
urine only
– 18
No. of patients testing qRT-PCR positive for
serum only
– 17
No. of patients testing qRT-PCR positive for
both urine and serum
– 13
No. of patients testing qRT-PCR negative for
both urine and serum
– 135
in multiplex with an internal control (PDV), in a LC480-II cycler
(Roche Life Science) (Table 1). The cut-off was set at <45 CT
values. Starting from 6 July 2016, only the primer pair targeting
the envelope was used in the qRT-PCR for confirmation of
ZIKV infection.
As the etiology of the clinical manifestations of patients
was still uncertain during the first 2 months of the outbreak
(December 2015 and January 2016), serum samples collected
from patients were also tested for DENV and CHIKV RNA
using FTD Dengue/Chik multiplex (Fast Track Diagnostics,
Esch-sur-Alzette, Luxembourg). Between December 2015 and
October 2016 paired urine samples (plasma if urine was not
available) with a target interval of ∼2 weeks were submitted
for testing. Starting from February 2016, either urine (matrix of
choice) or EDTA-plasma samples (if urine was not available) were
collected from patients.
In the period of 17 October 2016 until 26 April 2017,
after the implementation of commercial ZIKV diagnostic assays
at MLS, all samples of suspected ZIKV patients on Curaçao
were collected and tested at MLS. In this period, samples were
also collected from ZIKV-suspected patients on Bonaire by
Fundashon Mariadal and sent to MLS for testing. In contrast to
Curaçao, here it was chosen to collect paired serum and urine
samples on the same day, from a large number of patients. The
ZIKV diagnostic tests consisted of qRT-PCR and/or IgM/IgG
ELISA (Euroimmun, Lübeck, Germany). For qRT-PCR, total
nucleic acids were isolated using the MagNA Pure robotics
system (Roche Diagnostis) and tested in a qRT-PCR using FTD
Zika virus multiplex (Fast Track Diagnostics). Depending on
the number of days after the onset of symptoms at which the
patient was submitted for testing, the choice was made for either
qRT-PCR alone (0–7 days), qRT-PCR and serology (7–14 days),
or serology alone (≥14 days). However, as neither an ELISA-
positive IgM or IgG result for ZIKV in a DENV-endemic area
can be considered reliable due to the cross-reactivity known
to exist between DENV and ZIKV antibodies (36, 37), we
only considered positive results obtained in the qRT-PCR for
the analyses.
In the period of 17 October 2016 up to 8 November 2016,
plasma samples were tested, but from 9November 2016 onwards,
serum was chosen over EDTA-plasma due to its superior
practicality and durability in the lab, and recommendations made
by the World Health Organization (33). Urine was no longer
the matrix of choice as serum could be used in both qRT-PCR
and ELISA.
Curaçao can be divided into 65 geozones, which consist of
one or more neighborhoods. The patients’ geozone of residence
was used as a proxy for location and plotted on a map of
Curaçao using www.mapcustomizer.com. The ZIKV incidence
rates were determined for different age categories and the gender
of patients.
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Information such as presenting symptoms, day of onset,
and pregnancy was not properly documented by the general
practitioners on either Curaçao or Bonaire, and as a result, this
FIGURE 1 | Amount of ZIKV RNA detected in the first and second
ZIKV-positive urine samples of the paired samples submitted for testing by 32
individuals, expressed in terms of CT threshold 45 minus the CT determined
for the sample.
data could not be included in the analyses. Written consent
was provided by each individual submitting a urine, serum or
plasma sample for testing, and written consent for children under
16 years of age was provided by their parent or guardian. As
samples of patients were only collected for diagnostic purposes,
no additional ethical clearance was required for this study.
STATISTICAL ANALYSES
Paired samples were analyzed using a two-tailed paired t-test
and P-values equal to or less than 0.5 were considered to be
statistically significant.
RESULTS
Between 16 December 2015 and 26 April 2017, 3,833 samples of
2,820 individuals were collected by MLS on Curaçao. Of these,
2,044 samples belonging to 1,685 patients were tested in qRT-
PCR, resulting in 815 qRT-PCR positive samples, consisting of
781 positive ZIKV patients (Table 2). Testing of serum samples
of ZIKV-suspected patients on Curaçao was first initiated in
December 2015, during which two patients tested positive for
ZIKV using qRT-PCR. During the first 2 months of the outbreak
(December 2015 and January 2016), when serum samples were
also tested in DENV and CHIKV qRT-PCRs, four out of 87
FIGURE 2 | Absolute number of cases and prevalence of ZIKV-positive patients confirmed by qRT-PCR on Curaçao from mid-December 2015 to late April 2017
(A,B), and on Bonaire from mid-October 2016 to late April 2017 (C,D).
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TABLE 3 | Prevalence per month of qRT-PCR-confirmed ZIKV-positive patients
on Curaçao and Bonaire during the outbreak.
Month No. of
patients
tested
No. of
positive
patients
Prevalence
(%)
No. of
patients
tested
No. of
positive
patients
Prevalence
(%)
Curaçao Bonaire
16-Dec-15 15 2 13
Jan-16 66 3 5
Feb-16 176 19 11
Mar-16 104 20 19
Apr-16 68 13 19
May-16 66 24 36
June-16 69 21 30
July-16 56 13 23
Aug-16 151 72 48
Sept-16 172 78 45
Oct-16* 254 171 67 24 12 50
Nov-16 311 247 79 141 66 47
Dec-16 136 75 55 79 24 30
Jan-17 21 15 71 45 8 18
Feb-17 12 6 50 26 2 8
Mar-17 7 2 29 31 0 0
26-Apr-17 1 0 0 12 0 0
*For Bonaire samples were collected starting from 17-Oct-16.
ZIKV-suspected disease cases were confirmed as positive for
DENV instead (CT 26.6, 14.5, 29.5, and 34.4).
Of the 324 patients that submitted paired urine samples
between December 2015 and October 2016, 70 patients tested
positive for their first sample, while only 32 people still tested
qRT-PCR-positive for their second sample (Table 2), taken
between 11 and 17 days after the initial sample. This indicates that
for some patients in this cohort, ZIKV RNAwas still detectable in
urine for up to 17 days. Furthermore, there was a significant trend
in the decrease in the amount of virus shed in the urine over this
time period (P < 0.0001, paired t-test) (Figure 1). No significant
differences were found in the amount of virus shed in the urine
between men and women (data not shown).
During the period of 17 October 2016 until 26 April 2017,
a total of 744 samples were also collected from 382 individuals
on Bonaire and tested at MLS Curaçao. Of these, 599 samples
belonging to 358 patients were tested by qRT-PCR. A total of
129 samples consisting of 112 patients tested qRT-PCR positive
for ZIKV. Of the 262 patients that had both a serum and
urine sample taken on the same day, 183 had both samples
concomitantly tested in qRT-PCR. Of these, 13 patients were
positive for both serum and urine, while 17 patients tested
positive for only serum, and 18 for only urine. One hundred 35
patients tested negative for both (Table 2).
For both islands, the peak number of absolute cases occurred
in November 2016, with 247 qRT-PCR confirmed cases on
Curaçao (Figure 2A) and 66 qRT-PCR-positive cases on Bonaire
(Figure 2C; Table 3). In terms of prevalence, for Curaçao,
the peak (79%) also occurred in November 2016 (Figure 2B),
whereas for Bonaire the peak prevalence (50%) was in October
TABLE 4 | Characteristics of the 781 patients confirmed by qRT-PCR for ZIKV
infection on Curaçao between 16 December 2015 till 26 April 2017, and of the
112 patients confirmed on Bonaire between 17 October 2016 till 26 April 2017,
according to sex and age [with use of population demographics data from July
2017 (www.indexmundi.com)].
Characteristics N % Population
(N)
Incidence
per
100,000
population
Curaçao
Total population 149,648
ZIKV positive 781
Sex
Female 574 73.5 77,920 737
Male 207 26.5 71,728 289
Age group
0-14 70 9.0 29,935 234
15-24 67 8.6 21,450 312
25-54 476 60.9 55,181 863
55-64 106 13.6 20,482 518
65+ 62 7.9 22,600 274
Bonaire
Total population 19,179
ZIKV positive 112
Sex
Female 81 72.3 9261 875
Male 31 27.7 9918 313
Age group
0-14 6 5.4 3,359 179
15-24 15 13.4 2,105 713
25-54 75 67.0 9,198 815
55-64 11 9.8 2,552 431
65+ 5 4.5 2,194 228
2016 (Figure 2D; Table 3). Overall, a higher proportion of
women than men was diagnosed (∼73%) on both Curaçao and
Bonaire (Table 4), with incidence rates of 737 and 875 per
100,000, respectively. Furthermore, ZIKV was diagnosed mostly
in individuals in the age category of 25–54 years old on both
Curaçao (61%; incidence rate of 863 per 100,000) and Bonaire
(67%; incidence rate of 815 per 100,000) (Table 4).
To determine the distribution of ZIKV infections on Curaçao,
the locations of patients that tested positive for ZIKV by qRT-
PCR were plotted on a map of Curaçao. Locations of 197 patients
could not be pinpointed on the map. The map shows that the
majority of the ZIKV cases were clustered in the eastern part of
the island, particularly in Willemstad (Figure 3). Geozones with
a notable number of infections included Santa Rosa, Spaanse
Water, St. Michiel, Dominguito, Brievengat, Berg Altena, Tera
Cora, Stenen Koraal, and Groot Piscadera.
DISCUSSION
Despite the documented emergence of ZIKV into the Americas
in Brazil in May 2015, phylogenetic analyses estimate the
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FIGURE 3 | The locations of a selection of the patients on Curaçao that tested positive for ZIKV by qRT-PCR. The map was created by plotting the locations on www.
mapcustomizer.com.
introduction of the virus to be earlier, either between August
2013 and July 2014 (38) or between May and December 2013
(39). On Curaçao, according to our analyses, the first cases of
ZIKV were diagnosed in December 2015, a month before the first
notification to theWHOon 28 January 2016 (24), which indicates
that the virus, most likely introduced by travelers, emerged earlier
than officially reported. Given the rapid spread of the virus
throughout the Americas after its emergence in Brazil, Curaçao,
and Bonaire were not prepared for an outbreak of ZIKV, and
diagnostic assays had therefore not yet been implemented and
validated at MLS. This problem was circumvented by shipping
patient samples to the diagnostic laboratory of the EMC in
the Netherlands, a WHO Collaborating Centre for arboviruses.
Starting from October 2016, MLS Curaçao had implemented the
necessary commercial diagnostic qRT-PCR assay and ELISAs in
order to continue the diagnosis of ZIKV-suspected patients on
Curaçao and start with the diagnostics for Bonaire. Of note, this
study was not designed prospectively but performed in reaction
to a dynamic outbreak situation.
During this period, a switch was also made from urine to
serum for samples collected on Curaçao. Even though a few
studies have shown that urine was more sensitive for detection
of ZIKV by qRT-PCR compared to serum (30, 31), the data from
the paired serum and urine samples from Bonaire suggest that in
this cohort, these two matrices were required concomitantly to
increase the chance of ZIKV detection. As a result, it is possible
that many ZIKV cases on both Curaçao and Bonaire were missed
as here, paired urine and serum samples were not consistently
collected and/or tested in qRT-PCR. Even though many PCR-
negative samples from Curaçao and Bonaire had also been tested
in IgM/IgG ELISA, the cross-reactivity known to occur between
ZIKV and DENV antibodies makes diagnosis based on serology
difficult (36, 37) and could easily lead to false positives. As a
result, serology data of samples from patients collected 14 days
after onset of symptoms were not included in our analyses, and
our results are therefore very likely an underrepresentation of the
number of ZIKV cases on both islands. Another factor that may
have led to an underrepresentation of the total number of cases
is the fact that not all individuals that experienced symptoms
went to the general practitioner to get tested. Furthermore,
on Curaçao, three laboratories were involved in the diagnostic
testing of ZIKV patients, namely MLS, Analytisch Diagnostisch
Centrum (ADC) and Laboratorio de Medicos (LabdeMed). If all
the data were to be combined, the total number of ZIKV cases
would likely be much larger than presented in this article.
The peak of the ZIKV outbreak on Curaçao appeared to occur
in November 2016, both in terms of the absolute number of cases
and prevalence. For Bonaire, the peak in the absolute number of
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cases seemed to occur in November 2016 as well, while in terms
of prevalence it appeared to occur in October 2016. However, as
no ZIKV diagnostics was carried out for Bonaire between mid-
December 2015 and mid-October 2016, the data from October is
not reliable for comparison with the other months, and it can also
not be excluded that a larger number of people on Bonaire may
have been infected in one of the months preceding November.
Interestingly, during the reported outbreak of ZIKV on
Curaçao and Bonaire, no cases ofmicrocephaly or fatalities due to
ZIKV were reported. However, assuming a similar microcephaly
risk of 0.02% for pregnant women as calculated for Brazil (40),
and a fertility rate of ∼2.1 for Curaçao [based on data from 2011
(41)], which is equivalent to ∼2,100 live births per year, this
would have given 0.42 cases of microcephaly during the outbreak
on Curaçao (which lasted approximately a year). It is therefore
not surprising that no cases of ZIKV-related microcephaly were
observed in a population of only 150,000 and 19,000 people.
During the outbreak of ZIKV on both Curaçao and Bonaire,
almost three times more women than men were infected
with the virus. Infections occurred mostly in the age category
of 25–54 years old for both men and women. This higher
proportion of female infections during a ZIKV outbreak was
also reported in Surinam (42) and Rio de Janeiro in Brazil
(43). This disproportionate infection rate may be explained by
the increased testing of pregnant women due to the concerns
about microcephaly and other risks for the unborn babies.
However, such a trend was also demonstrated in Rio de
Janeiro during a DENV outbreak (43), where women were
30% more likely to be diagnosed with DENV than men. One
explanation suggested by this study was that women are more
conscientious about their health and therefore more likely to
visit a general practitioner. Nonetheless, another possibility,
as also speculated upon in the Coelho study (43), is that for
ZIKV, a higher amount of male-to-female sexual transmissions
occur in comparison to female-to-male transmissions. Infection
of females by ZIKV via semen has already been demonstrated
(1–3), and even though ZIKV has also been detected in the
female genital tract and vaginal secretions (44–47), the ability
of the virus to productively infect males via vaginal secretions
during sexual intercourse has not yet been demonstrated.
Furthermore, the influence of female reproductive hormones on
ZIKV replication and transmission should also be investigated,
as progestins have recently been shown to promote infection
of HIV within the female reproductive tract of non-human
primates (48).
In order to obtain an impression of the distribution of the
number of ZIKV cases on Curaçao, the locations of the patients
were plotted on a map. The majority of the cases were located in
the east of the island, which may be the result of a reporting bias
caused by a higher population density in the east (Willemstad)
(41). Nonetheless, for geozones that contained the largest amount
of ZIKV cases, no particular trend in terms of population density
or average gross monthly income per household was identified
(data not shown). It is possible that the geospatial distribution
of ZIKV cases is a reflection of the presence of ZIKV-infected
mosquitoes; however, as many inhabitants of Curaçao travel to
different parts of the island on a daily basis, it is not possible
to determine with certainty the location of transmission. Besides
mosquito transmission, sexual transmission of ZIKV may also
have influenced the geospatial distribution of cases on the island.
CONCLUSIONS
As Curaçao and Bonaire are (potential) hot-spots for emerging
and re-emerging arbovirus infections, it is important that the
islands are prepared for future outbreaks by implementing the
appropriate diagnostic tools in advance. However, in addition to
effective diagnostics, it is imperative that the right infrastructure
is also put in place to allow communication during an outbreak
setting and to facilitate the implementation of risk-reduction
activities in order to deal with any infectious disease that may
emerge in the future.
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